Coherus Oncology CHRS Institutional Ownership

Ownership Summary

Coherus Oncology, Inc. (NASDAQ:CHRS) appears in 155 institutional 13F filings for the quarter ending March 2026.

• They owned 43.4% of outstanding stock in March 2026, down from 44.1% the prior quarter.
• They increased total shares held in Coherus Oncology by 44.15% from last quarter, and the number of investors in CHRS increased 30.25% annually.
• Of these 155 funds, 86 grew their exposure to Coherus Oncology, 41 cut back, and 28 maintained positions.
• In total, institutional investors held 59.14Mn shares in Coherus Oncology as of March 2026, up by 18.11Mn shares quarter on quarter, and down 6.35Mn shares year over year.
• BlackRock, Inc. leads ownership in CHRS with 10.37Mn shares as of March 31, 2026, equal to 7.6% of outstanding shares.
• The biggest buyers of Coherus Oncology for the quarter ending March 2026 included VANGUARD CAPITAL MANAGEMENT LLC (5.45Mn), Samsara BioCapital, LLC (3.43Mn), Alyeska Investment Group, L.P. (2.25Mn), TWO SIGMA INVESTMENTS, LP (1.8Mn), Propel Bio Management, LLC (1.42Mn).
• Leading sellers of Coherus Oncology shares for the quarter ending March 2026 were TANG CAPITAL MANAGEMENT LLC (837.76K), JANE STREET GROUP, LLC (563.02K), MILLENNIUM MANAGEMENT LLC (348.46K), BlackRock, Inc. (197.64K), PANAGORA ASSET MANAGEMENT INC (160.96K).
• According to Business Quant data, leading holders of CHRS for March 2026 are BlackRock, Inc. (10.37Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.45Mn), Samsara BioCapital, LLC (3.43Mn), GEODE CAPITAL MANAGEMENT, LLC (3.12Mn), Kohlberg Kravis Roberts & Co. L.P. (3.04Mn), State Street Corp (2.33Mn), TWO SIGMA INVESTMENTS, LP (2.3Mn), Alyeska Investment Group, L.P. (2.25Mn), CM Management, LLC (2.1Mn), C WorldWide Group Holding A/S (1.93Mn).